Brian Goff is the CEO of Agios Pharmaceuticals, appointed to the role in August 2022. He has a solid background in the pharmaceutical industry, previously serving as the Executive Vice President at Alexion Pharmaceuticals, where he led teams across various...

Brian Goff is the CEO of Agios Pharmaceuticals, appointed to the role in August 2022. He has a solid background in the pharmaceutical industry, previously serving as the Executive Vice President at Alexion Pharmaceuticals, where he led teams across various global markets. Brian holds an MBA from the prestigious Wharton School at the University of Pennsylvania, equipping him with a strong foundation in business management. Under his leadership, Agios focuses on reaching ambitious performance goals, and recently he earned a total compensation package of over $3.4 million, reflecting the company’s success and his impact. One interesting highlight is his impressive stock options and performance-based incentives that link his pay directly to the company’s achievements. Brian is known for being results-driven, emphasizing the importance of aligning executive compensation with the company's performance. Beyond numbers, he is focused on enhancing treatments for patients, showcasing his commitment to improving healthcare through innovation.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Agios Pharmaceuticals CEOs

A

Brian Goff

CEO of Agios Pharmaceuticals

Education

MBA from the Wharton School at the University of Pennsylvania

Sector of Economy

Healthcare

Born

January 1, 1969 - 56 years ago

CEO of Agios Pharmaceuticals for

2 years 11 months (Aug 2022 - Present)

Previous Experience

Executive Vice President, Chief Commercial and Global Operations Officer at Alexion Pharmaceuticals, Inc.

Rivals

Competitors/colleagues of Brian Goff

Holdings

See how much did Brian Goff make over time.

Brian Goff's holdings in Agios Pharmaceuticals are noteworthy. As of 2023, he has accumulated a significant number of vested stocks, amounting to a value of approximately $1.3 million. Over the past year, his stake has seen fluctuations as the company...

Brian Goff's holdings in Agios Pharmaceuticals are noteworthy. As of 2023, he has accumulated a significant number of vested stocks, amounting to a value of approximately $1.3 million. Over the past year, his stake has seen fluctuations as the company has gone through various milestones. The majority of his wealth is closely tied to performance-based stock units and options. Just a year ago, in 2022, he entered with considerable stock options, showing strong potential value if he successfully meets company goals. His financial interests are aligned with shareholder interests, making his investment in Agios highly relevant to his leadership role.

Loading...

Total Stock Sold

$2.25M

AGIO

$2.25M

68,690 AGIO shares

What if they kept their stock?

If Brian Goff didn't sell their stock, today they would have:
Extra AGIO68,690 shares worth $3.63M.
This is 61.48% and $1.38M more than what they got when they sold the stock.

Insider Trading

See recent insider trades of Brian Goff.

AGIO

$474.14K

AGIO at $42.75/share

Aug 8, 2024

Sale

NTLA

15,409 shares

NTLA

Jun 13, 2024

Received

AGIO

$591.70K

AGIO at $48.84/share

Jun 5, 2024

Sale

AGIO

$135.36K

AGIO at $32.57/share

Mar 1, 2024

Sale

AGIO

$165.22K

AGIO at $21.64/share

Jan 20, 2024

Sale

AGIO

$277.40K

AGIO at $22.99/share

Jan 5, 2024

Sale

AGIO

$259.34K

AGIO at $25.48/share

Aug 8, 2023

Sale

AGIO

$324.69K

AGIO at $28.36/share

Jun 28, 2023

Sale

Compensation History

See how much did Brian Goff make over time.

In 2023, Brian Goff's compensation was reported at approximately $3.4 million, demonstrating a strong pay-for-performance structure. His salary was about $798,250, complemented by a performance bonus of $648,179, reflecting a solid overall performance score of 116%. A significant portion of his compensation comes from vested stock awards, valued at around $1.3 million this year itself. The stock options granted to him are set to vest based on the company achieving specific operational and financial milestones, indicating that his compensation directly correlates with the success of Agios. This structure not only incentivizes him but also aligns his interests with those of the shareholders.

Year

2023

Total Compensation

$2.78M

Salary

$798.25K

Board Justification

The compensation philosophy emphasizes a pay-for-performance approach, aligning executive compensation with company performance and shareholder interests.

Bonus

$648.18K

Board Justification

The bonus is based on the company's performance against predetermined annual goals, with an overall performance score of 116% for 2023.

Other

$12.55K

Board Justification

Other compensation includes a matching contribution under the company’s 401(k) plan and the dollar value of company-paid life insurance and disability insurance premiums.

Restricted Stock

$1.32M(48.22K RSU)

Board Justification

The stock awards that vested in 2023 were based on the achievement of specified performance milestones.

Performance Metrics

The performance metrics include achieving specific research, clinical, operational, and financial goals.

Other Agios Pharmaceuticals CEOs

Here are other CEOs of Agios Pharmaceuticals

Jacqualyn A. Fouse, Ph.D.

Ex-CEO of Agios Pharmaceuticals

March 2019 - August 2022